Maria Palasis, PhD, is Chief Executive Officer and Board Director of Lyra Therapeutics, a combination product biotechnology company she took public in 2020.
Maria is also on the Advisory Board of Beta Bionics. Prior to Lyra Therapeutics, she was President, CEO, and Board Director of both Arsenal Medical and its spin-out, 480 Biomedical. Maria also served in senior leadership roles at Boston Scientific Corporation, focused on the development of drug-device combination products. In 2021, she was elected to the National Academy of Engineering for outstanding contributions to the design of medical devices and drug delivery systems.
Maria holds a BS and PhD in Chemical Engineering from the University of Cincinnati and completed her postdoctoral fellowship in Molecular Biology at the University of Cincinnati School of Medicine.